• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卢美他尼/依伐卡托对囊性纤维化患者呼吸道细菌和真菌病原体的影响：瑞典一项前瞻性多中心队列研究。

Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden.

机构信息

Stockholm CF Centre, Karolinska University Hospital Huddinge, Stockholm, Department of Clinical Science, Intervention and Technology, Sweden.

Division of Pediatrics, Karolinska Institutet, Alfred Nobels Allé 8, Stockholm 171 77, Sweden.

出版信息

Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241254090. doi: 10.1177/17534666241254090.

DOI:10.1177/17534666241254090
PMID:38780228
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11119492/
Abstract

BACKGROUND

A significant decline in pulmonary exacerbation rates has been reported in CF patients homozygous for F508del treated with lumacaftor/ivacaftor. However, it is still unclear whether this reduction reflects a diminished microbiological burden.

OBJECTIVES

The aim of this study was to determine the impact of lumacaftor/ivacaftor on the bacterial and fungal burden.

DESIGN

The study is a prospective multicenter cohort study including 132 CF patients homozygous for F508del treated with lumacaftor/ivacaftor.

METHODS

Clinical parameters as well as bacterial and fungal outcomes 1 year after initiation of lumacaftor/ivacaftor were compared to data from 2 years prior to initiation of the treatment. Changes in the slope of the outcomes before and after the onset of treatment were assessed.

RESULTS

Lung function measured as ppFEV1 ( < 0.001), body mass index (BMI) in adults ( < 0.001), and BMI -score in children ( = 0.007) were improved after initiation of lumacaftor/ivacaftor. In addition, the slope of the prevalence of ( = 0.007) and ( < 0.001) shifted from positive to negative, that is, became less prevalent, 1 year after treatment, while the slope for ( = 0.009), spp ( = 0.026), and ( < 0.001) shifted from negative to positive.

CONCLUSION

The current study showed a significant improvement in clinical parameters and a reduction of some of CF respiratory microorganisms 1 year after starting with lumacaftor/ivacaftor. However, no significant changes were observed for , or , key pathogens in the CF context.

摘要

背景

在接受 lumacaftor/ivacaftor 治疗的 F508del 纯合子 CF 患者中，肺部恶化率显著下降。然而，目前尚不清楚这种减少是否反映了微生物负担的减轻。

目的

本研究旨在确定 lumacaftor/ivacaftor 对细菌和真菌负担的影响。

设计

这是一项前瞻性多中心队列研究，包括 132 名接受 lumacaftor/ivacaftor 治疗的 F508del 纯合子 CF 患者。

方法

比较 lumacaftor/ivacaftor 治疗开始前 1 年与治疗开始前 2 年的临床参数以及细菌和真菌结果。评估治疗前后结果斜率的变化。

结果

肺功能（ppFEV1）（<0.001）、成人 BMI（<0.001）和儿童 BMI 评分（=0.007）在开始使用 lumacaftor/ivacaftor 后得到改善。此外， （=0.007）和 （<0.001）的流行率斜率从正变为负，即在治疗 1 年后变得不那么流行，而 （=0.009）、 spp（=0.026）和 （<0.001）的斜率从负变为正。

结论

本研究表明，在开始使用 lumacaftor/ivacaftor 1 年后，临床参数显著改善，一些 CF 呼吸道微生物数量减少。然而，对于 CF 环境中的关键病原体 或 ，没有观察到显著变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/058eb4a03fc5/10.1177_17534666241254090-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/9c4f43614a49/10.1177_17534666241254090-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/6ee22222c561/10.1177_17534666241254090-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/6752680449ee/10.1177_17534666241254090-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/09ebf778b0a9/10.1177_17534666241254090-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/058eb4a03fc5/10.1177_17534666241254090-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/9c4f43614a49/10.1177_17534666241254090-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/6ee22222c561/10.1177_17534666241254090-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/6752680449ee/10.1177_17534666241254090-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/09ebf778b0a9/10.1177_17534666241254090-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/11119492/058eb4a03fc5/10.1177_17534666241254090-fig5.jpg

相似文献

1
Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden.卢美他尼/依伐卡托对囊性纤维化患者呼吸道细菌和真菌病原体的影响：瑞典一项前瞻性多中心队列研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241254090. doi: 10.1177/17534666241254090.
2
Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.囊性纤维化和晚期肺病患者从 lumacaftor/ivacaftor 治疗中获益。
Pediatr Pulmonol. 2020 Dec;55(12):3364-3370. doi: 10.1002/ppul.25059. Epub 2020 Sep 19.
3
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.在 F508del-CFTR 纯合子的 6-11 岁囊性纤维化患者中， lumacaftor 和 ivacaftor 的疗效和安全性：一项随机、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9.
4
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.在囊性纤维化跨膜电导调节因子纯合子 F508del-CFTR 的 2-5 岁儿童中， lumacaftor 和 ivacaftor 联合治疗的安全性、药代动力学和药效学：一项开放标签的 3 期研究。
Lancet Respir Med. 2019 Apr;7(4):325-335. doi: 10.1016/S2213-2600(18)30460-0. Epub 2019 Jan 24.
5
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.针对携带F508del-CFTR突变纯合子的6至11岁囊性纤维化儿童，鲁马卡托-依伐卡托治疗的长期安全性和有效性：一项3期开放标签扩展研究。
Lancet Respir Med. 2021 Jul;9(7):721-732. doi: 10.1016/S2213-2600(20)30517-8. Epub 2021 Jan 28.
6
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.依库珠单抗/ivacaftor 联合治疗对肺功能亚组纯合子 Phe508del CFTR 囊性纤维化患者的疗效和安全性：一项汇总分析。
Lancet Respir Med. 2016 Aug;4(8):617-626. doi: 10.1016/S2213-2600(16)30121-7. Epub 2016 Jun 10.
7
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.Lumacaftor/ivacaftor 疗法未能增加 F508del/F508del CF 患者的胰岛素分泌。
J Cyst Fibros. 2021 Mar;20(2):333-338. doi: 10.1016/j.jcf.2020.09.001. Epub 2020 Sep 8.
8
Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.利那洛肽治疗在囊性纤维化跨膜电导调节因子功能对囊性纤维化纯合子 Phe508del 患者的影响。
Am J Respir Crit Care Med. 2018 Jun 1;197(11):1433-1442. doi: 10.1164/rccm.201710-1983OC.
9
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.鲁马卡托/依伐卡托治疗F508del-CFTR杂合型囊性纤维化患者
Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC.
10
An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.一项观察性研究：在开始使用 Lumacaftor/Ivacaftor 的囊性纤维化患者中的结局和耐受性。
Ann Am Thorac Soc. 2017 Nov;14(11):1662-1666. doi: 10.1513/AnnalsATS.201701-058OC.

引用本文的文献

1
Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.在患有囊性纤维化且有烟曲霉感染史的患者中，接受依列卡福/替扎卡福/艾伐卡福治疗后的呼吸结局和曲霉血清学检查
Lung. 2025 Jan 6;203(1):24. doi: 10.1007/s00408-024-00781-4.
2
Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis.噬菌体疗法：一种治疗囊性纤维化中多重耐药菌感染的替代方法。
Int J Mol Sci. 2024 Jul 30;25(15):8321. doi: 10.3390/ijms25158321.

本文引用的文献

1
Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.依伐卡托与泰它西普和艾乐卡托联合治疗囊性纤维化肺部后纵向微生物和分子动态变化
Respir Res. 2023 Dec 16;24(1):317. doi: 10.1186/s12931-023-02630-z.
2
Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist.依列卡福妥/替扎卡福妥/依伐卡托（ETI）用于囊性纤维化的长期治疗：临床结局改善，但感染和炎症仍然存在。
Eur Respir J. 2023 Aug 3;62(2). doi: 10.1183/13993003.01008-2023. Print 2023 Aug.
3
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
依伐卡托/泰他卡托/艾美卡替三联复方制剂对囊性纤维化患者痰液黏弹性特性、气道感染和炎症的纵向影响。
Eur Respir J. 2023 Aug 3;62(2). doi: 10.1183/13993003.02153-2022. Print 2023 Aug.
4
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.药物改善 CFTR 功能可迅速降低痰中病原体密度，但肺部感染通常持续存在。
J Clin Invest. 2023 May 15;133(10):e167957. doi: 10.1172/JCI167957.
5
Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization.鲁马卡托-依伐卡托对囊性纤维化患者气道微生物群-真菌群及炎症的影响似乎与铜绿假单胞菌慢性定植有关。
Microbiol Spectr. 2023 Mar 27;11(2):e0225122. doi: 10.1128/spectrum.02251-22.
6
Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.依洛尤单抗治疗家族性高胆固醇血症的效果和安全性：一项随机对照试验的荟萃分析
Pediatr Pulmonol. 2023 Mar;58(3):825-833. doi: 10.1002/ppul.26261. Epub 2022 Dec 9.
7
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights.用于治疗囊性纤维化的依列卡福/替扎卡福/艾伐卡福的出现：对曲霉相关疾病有何影响？初步见解。
J Cyst Fibros. 2022 Nov;21(6):1084-1085. doi: 10.1016/j.jcf.2022.09.007. Epub 2022 Sep 21.
8
Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study.依列卡福妥-替扎卡福妥-依伐卡托作为囊性纤维化治疗的最后前沿：病例对照研究中临床和微生物学意义的界定
Pharmaceuticals (Basel). 2022 May 14;15(5):606. doi: 10.3390/ph15050606.
9
A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung.微生物生态位空间的重构与囊性纤维化肺部的 Elexacaftor-Tezacaftor-Ivacaftor 治疗相关。
J Cyst Fibros. 2022 Nov;21(6):996-1005. doi: 10.1016/j.jcf.2021.11.003. Epub 2021 Nov 22.
10
Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients.鲁马卡托/依伐卡托改变了囊性纤维化患者的肺部微生物组和代谢组。
ERJ Open Res. 2021 Apr 19;7(2). doi: 10.1183/23120541.00731-2020. eCollection 2021 Apr.